Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

SGRY , AROAF
Sort by: Date|Relevance

Transenterix Shares Trade Up 25% on FDA Filing for First Machine Vision System in Robotic Surgery

Shares of Transenterix opened 50% higher after the company reported that it has submitted a 510(k) submission to the FDA for the first machine vision system for use in robotic surgery. This morning, medical device company TransEnterix Inc. (TRXC:NYSE.American) , whic...

Soliton Shares Rise on Announcement It Will Report Clinical Data at National Dermatology Conference

Soliton Inc. shares traded 10% higher today after advising that later this month it will present the data from clinical trials for its Rapid Acoustic Pulse device used in the treatment of keloid and hypertrophic scars at the American Society for Dermatologic Surgery Annual Mee...

Buzz on the Bullboards: Bulls on the Buzzboards

Do you believe in parallel dimensions, alternate realities? Somewhere where there is no COVID, European tensions are just that – tense, market volatility is kept to a minimum. It is here, perhaps, in the inversed Buzz, where everything is “fine”...

Imagin Medical Poised for Breakout with Bladder Cancer Detection Device in FDA Approval Process

A new advancement in bladder-related endoscopic surgery is endorsed and de-risked. You don't often hear about it, but bladder cancer is the sixth most common cancer in the U.S., with approximately 80,000 cases reported every year, and some 600,000 Americans living in ...

A New Solution for the Multibillion-Dollar Bladder Cancer Problem

Bladder cancer is the sixth-most prevalent cancer in North America and has a recurrence rate greater than 50%, making it the most expensive cancer to treat. All-in costs in the US are around $4 billion and roughly 80,000 new American cases are reported each year, with 350,000...

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...

The future of the textile marketplace

Countries manufacturing textiles will likely acquire a healthy dose of revenue into their economy. According to fiber2fashion.com , the population is increasing to 9.5 billion, with the global apparel market reaching over $2 trillion by 2025. Given the massive gr...

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data

EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. ...

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data

Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. Ocular Ther...

CytoSorbents Shares Trade 20% Higher as FDA Grants CytoSorb EUA for COVID-19

Shares of CytoSorbents traded higher setting a new 52-week intraday high price after the company reported that the FDA granted emergency use authorization for CytoSorb for use in patients with COVID-19. Critical care immunotherapy company CytoSorbents Corp....
1 2 3 4